Although PPAR-β/δ agonists have been shown to cross the blood–brain barrier and modulate oxidative stress and proinflammatory responses associated with acute and chronic CNS disorders, overall, there are only a few studies evaluating the action of the PPAR-β/δ receptor in brain tumors [71]. This evidence concerns the gene PPARD and brain neoplasm.